13D Filing: Sandor Capital Master Fund, L.P. and Medical Alarm Concepts Holdings Inc

Page 4 of 6 – SEC Filing

 

Item
1. Security and Issuer

 

The
title and class of equity securities to which this Schedule 13D relates is Common Stock, par value $0.0001 per share (the “Common
Stock”), of Wearable Health Solutions, Inc., a Nevada corporation (the “Issuer”). The address of the principal
executive offices of the Issuer is 200 West Church Road, Suite B, King of Prussia, Pennsylvania 19406.

 

Item
2. Identity and Background

 

(a)
This statement is being filed by Sandor and John S. Lemak (“Lemak”), Manager of Sandor (collectively, the “Reporting
Persons”). The Reporting Persons are making a joint filing because they may be deemed to be a group pursuant to Section
13 of the Exchange Act.

 

(b)
The Reporting Persons’ business address is 2828 Routh Street, Suite 500, Dallas, TX 75201.

 

(c)
Sandor, a Texas corporation, was formed to invest in private and public companies for capital appreciation. The principal occupation
of Lemak, Manager of Sandor, is an investor and general partner of Sandor Advisors, LLC.

 

(d)
During the last five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations
or similar misdemeanors).

 

(e)
During the last five years, the Reporting Persons have not been a party to a civil proceeding of a judicial or administrative
body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations
with respect to such laws.

 

(f)
United States.

 

Item
3. Source and Amount of Funds or Other Considerations

 

On
April 21, 2016, the Reporting Persons purchased one unit of the Issuer’s securities at a purchase price of $400,000 which
consisted (i) 400,000 shares of Series D Preferred Stock, par value $0.0001 per share, each convertible into 100 shares of the
Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) one warrant (the “Warrant”)
to purchase 40,000,000 shares of Common Stock, $0.001 par value per share, at an exercise price of $0.01 per share. The one unit
was purchased with the Reporting Persons’ personal funds. On October 26, 2016, the Reporting Persons partially exercised
the Warrant and received 5,000,000 shares of Common Stock. On December 28, 2016, the Reporting Person purchased 25,000 shares
of Common Stock at $0.089 per share. On December 29, 2016, the Reporting Person purchased 31,000 shares of Common Stock at $0.069
per share. On December 30, 2016, the Reporting Person purchased 38,000 shares of Common Stock at $0.102 per share.

 

Item
4. Purpose of Transaction

 

All
of the Issuer’s securities owned by the Reporting Persons have been acquired for investment purposes only. The Reporting
Persons have no present plans or proposals that relate to or would result in any of the actions required to be described in subsections
(a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time, review or reconsider its position with respect
to the Issuer and formulate plans or proposals with respect to any of such matters, but has no present intention of doing so.

 

Item
5. Interest in Securities of the Issuer

 

(a)
The Reporting Persons beneficially own 5,094,000 shares or 10.21% (Based upon 49,874,177 shares of common stock issued and outstanding
as of May 15, 2017, as reported in the Issuer’s Form 10-Q/A filed with the Securities and Exchange Commission on May 23,
2017) of the Issuer’s Common Stock (1).

 

(b)
The Reporting Persons may be deemed to hold sole voting and dispositive power over 5,094,000 shares of the Issuer’s voting
capital stock.

 

(c)
Not applicable.

 

(d)
To the best knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive, or the power
to direct the receipt of, dividends from, or the proceeds from the sale of the shares reported in Item 5(a).

 

(e)
Not applicable.

 

(1) Represents
5,094,000 shares of common stock held by Sandor. Excludes (i) 35,000,000 shares of common stock issuable upon exercise of
outstanding warrants held by Sandor and (ii) 40,000,000 shares of common stock issuable upon conversion of 400,000 shares
of Series D Convertible Preferred Stock held by Sandor. The outstanding warrants and Series D Convertible Preferred Stock
contain a 4.99% beneficial ownership blocker. John Lemak is the Manager of Sandor and is such capacity has voting and depository
power over securities held by such entity.

 

Item
6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

Other
than as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the
Reporting Persons and any other person with respect to any securities.

 

Item
7. Material to Be Filed as Exhibits

 

Not
applicable.

 

Follow Wearable Health Solutions Inc.